The Effect of Non-Alcoholic Fatty Liver Disease on Weight Loss and Resolution of Obesity-Related Disorders After Bariatric Surgery
Tóm tắt
Patients undergoing bariatric surgery have a high incidence of non-alcoholic fatty liver disease (NAFLD). However, the effect of NAFLD or non-alcoholic steatohepatitis (NASH) on the weight loss and resolution of obesity-related disorders is a matter of debate. In this study, we compare the long-term outcomes after bariatric with the presence of NAFLD in the liver biopsy at the time of surgery. The follow-up was available for 226 out of 288 patients. The mean follow-up time was 24.9 (± 13.6) months. The baseline histology showed that 112 patients (38.9%) had no NASH, 70 (24.3%) were borderline, and 106 (36.8%) had NASH. At follow-up, the mean BMI dropped from (52 ± 10.2) to (36.6 ± 8) kg/m 2. Excess weight loss (EWL) was similar in all NAFLD groups. Type 2 diabetes mellitus dropped from 35.7 to 11.4%, hypertension from 65.6 to 36.7%, hyperlipidemia from 62.3 to 33%, and obstructive sleep apnea from 37.5 to 14.9%. Only hyperlipidemia was significantly associated with NASH compared to the groups with no NASH or borderline NASH (p value = 0.002 and p value = 0.04, respectively) during the first two years of follow-up. The beneficial effects of bariatric surgery are evident across all patients with NAFLD. Patients with NASH have comparable outcomes regarding weight loss and resolution of obesity-related comorbidities.
Tài liệu tham khảo
Strauss RS, Pollack HA (2001) Epidemic increase in childhood overweight, 1986–1998. JAMA 286(22):2845–2848
Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C et al (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384(9945):766–781
Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, Thompson A et al (2011) Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 377(9771):1085–1095
Després JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E et al (2008) Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 28(6):1039–1049
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116(6):1413–1419
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142(7):1592–1609
Loomba R, Sanyal AJ (2013) The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10(11):686–690
Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM et al (2015) Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148(3):547–555
Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, Caldwell SH et al (2018) Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 48(7):696–703
Sumida Y, Nakajima A, Itoh Y (2014) Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 20(2):475–485
Simo KA, McKillop IH, McMillan MT, Ahrens WA, Walters AL, Thompson KJ et al (2014) Does a calculated “NAFLD fibrosis score” reliably negate the need for liver biopsy in patients undergoing bariatric surgery? Obes Surg 24(1):15–21
Machado MV, Diehl AM (2016) Pathogenesis of Nonalcoholic Steatohepatitis. Gastroenterology 150(8):1769–1777
Shalhub S, Parsee A, Gallagher SF, Haines KL, Willkomm C, Brantley SG et al (2004) The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients. Obes Surg 14(1):54–59
Rheinwalt KP, Drebber U, Schierwagen R, Klein S, Neumann UP, Ulmer TF et al (2020) Baseline presence of NAFLD predicts weight loss after gastric bypass surgery for morbid obesity. J Clin Med 9(11):3430
Sabench F, Bertran L, Vives M, París M, Aguilar C, Martínez S, et al (2022) NASH presence is associated with a lower weight loss one and 2 years after bariatric surgery in women with severe obesity. Obes Surg 32:3313–3323
Khajeh E, Aminizadeh E, Eslami P, Ramouz A, Kulu Y, Billeter AT et al (2022) Outcomes of bariatric surgery in patients with obesity and compensated liver cirrhosis. Surg Obes Relat Dis 18(6):727–737
Runkel N, Colombo-Benkmann M, Huttl TP, Tigges H, Mann O, Flade-Kuthe R et al (2011) Evidence-based German guidelines for surgery for obesity. Int J Colorectal Dis 26(4):397–404
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6):1313–1321
Angrisani L, Santonicola A, Iovino P, Vitiello A, Higa K, Himpens J et al (2018) IFSO Worldwide Survey 2016: primary, endoluminal, and revisional procedures. Obes Surg 28(12):3783–3794
Kroh M, Liu R, Chand B (2007) Laparoscopic bariatric surgery: what else are we uncovering? Liver pathology and preoperative indicators of advanced liver disease in morbidly obese patients. Surg Endosc 21(11):1957–1960
Golzarand M, Toolabi K, Farid R (2017) The bariatric surgery and weight losing: a meta-analysis in the long- and very long-term effects of laparoscopic adjustable gastric banding, laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy on weight loss in adults. Surg Endosc 31(11):4331–4345
Cazzo E, Jimenez LS, Gestic MA, Utrini MP, Chaim FHM, Chaim FDM et al (2018) Type 2 diabetes mellitus and simple glucose metabolism parameters may reliably predict nonalcoholic fatty liver disease features. Obes Surg 28(1):187–194
Chatrath H, Vuppalanchi R, Chalasani N (2012) Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis 32(1):22–29
Corey KE, Vuppalanchi R, Wilson LA, Cummings OW, Chalasani N (2015) NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels. Aliment Pharmacol Ther 41(3):301–309
Rabl C, Campos GM (2012) The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin Liver Dis 32(1):80–91
Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M (2010) Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010:CD007340
Aminian A, Al-Kurd A, Wilson R, Bena J, Fayazzadeh H, Singh T et al (2021) Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA 326(20):2031–2042
Patel P, Abate N (2013) Body fat distribution and insulin resistance. Nutrients 5(6):2019–2027
Mato JM, Alonso C, Noureddin M, Lu SC (2019) Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. World J Gastroenterol 25(24):3009–3020
Deprince A, Haas JT, Staels B (2020) Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab 42:101092
Tilg H, Adolph TE, Dudek M, Knolle P (2021) Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 3(12):1596–1607